Xeris Biopharma Holdings XERS Institutional Ownership

Ownership Summary

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has 226 institutional investors that have filed 13F reports for the period ending March 2026.

• Collectively, these holders controlled 55.3% of Xeris Biopharma Holdings's outstanding shares in March 2026, down from 62.5% in December 2025.
• Their total shares held in XERS increased 12.52% from the prior quarter, while the number of investors in Xeris Biopharma Holdings increased 13.0% year over year.
• Activity in XERS broke down as 139 buyers, 56 sellers, and 31 unchanged among 226 total holders.
• Institutional investors collectively held 94.26Mn shares in Xeris Biopharma Holdings as of March 2026, up by 10.48Mn shares quarter on quarter, and down 941.31K shares year over year.
• BlackRock, Inc. is the top holder of Xeris Biopharma Holdings as of March 31, 2026, with 12.95Mn shares representing 7.59% of outstanding stock.
• The biggest buyers of Xeris Biopharma Holdings for the quarter ending March 2026 included ARMISTICE CAPITAL, LLC (1.91Mn), Parkman Healthcare Partners LLC (1.72Mn), MILLENNIUM MANAGEMENT LLC (1.41Mn), Rosalind Advisors, Inc. (1.12Mn), UBS Group AG (1.04Mn).
• Leading sellers of Xeris Biopharma Holdings shares for the quarter ending March 2026 were DRIEHAUS CAPITAL MANAGEMENT LLC (2.08Mn), Goldman Sachs Group Inc (1.52Mn), Connor, Clark & Lunn Investment Management Ltd. (651.07K), Prudential Financial Inc (561.81K), VOLORIDGE INVESTMENT MANAGEMENT, LLC (441.01K).
• According to Business Quant data, leading holders of XERS for March 2026 are BlackRock, Inc. (12.95Mn), D. E. Shaw & Co., Inc. (7.79Mn), State Street Corp (4.66Mn), GEODE CAPITAL MANAGEMENT, LLC (4.29Mn), Qube Research & Technologies Ltd (4.11Mn), Rosalind Advisors, Inc. (3.23Mn), Nuveen, LLC (2.92Mn), Morgan Stanley (2.57Mn), MILLENNIUM MANAGEMENT LLC (2.27Mn), WELLINGTON MANAGEMENT GROUP LLP (2.17Mn).